Zheng Weili, Lai Guilan, Lin Qiaochu, Issah Mohammed Awal, Fu Haiying, Shen Jianzhen
Fujian Provincial Key Laboratory on Hematology, Fujian Medical Center of Hematology, Fujian Institute of Hematology, Clinical Research Center for Hematological Malignancies of Fujian Province, Fujian Medical University Union Hospital, Fuzhou, China.
Front Cell Dev Biol. 2021 Oct 27;9:735855. doi: 10.3389/fcell.2021.735855. eCollection 2021.
The activated B cell (ABC) and germinal center B cell (GCB) subtypes of diffuse large B cell lymphoma (DLBCL) have different gene expression profiles and clinical outcomes, and miRNAs have been reported to play important roles in tumorigenesis, progression, and metastasis. This study aimed to explore the differentially expressed miRNAs and target genes in the two main subtypes of DLBCL. Hub miRNAs were identified by constructing a regulatory network, and experiments and peripheral blood samples of DLBCL were used to explore the functions and mechanisms of differential miRNAs and mRNAs. Differentially expressed miRNAs and genes associated with the two DLBCL subtypes were identified using GEO datasets. Weighted gene co-expression network analysis shows that one gene module was associated with a better prognosis of patients with the GCB subtype. Through the construction of a regulatory network and qPCR verification of clinical samples and cell lines, miR-129-5p was identified as an important differential miRNA between the ABC and GCB subtypes. The negative relationship between miR-129-5p and ARID3A in DLBCL was confirmed using luciferase reporter assays. Overexpression of miR-129-5p and knockdown of ARID3A inhibited the proliferation of SU-DHL-2 (ABC-type) cells and promoted their apoptosis through the JAK and STAT6 signaling pathways. In addition, inhibition of miR-129-5p and overexpression of ARID3A promoted the proliferation and reduced apoptosis of DB and SU-DHL-6 (GCB-type) cells. Inhibition of miR-129-5p and overexpression of ARID3A in DB and SU-DHL-6 promoted immune escape by increasing PD-L1 expression, which was transcriptionally activated by ARID3A. In conclusion, we showed for the first time that the mir-129-5P/ARID3A negative feedback loop modulates DLBCL progression and immune evasion by regulating PD-1/PD-L1.
弥漫性大B细胞淋巴瘤(DLBCL)的活化B细胞(ABC)和生发中心B细胞(GCB)亚型具有不同的基因表达谱和临床结局,且据报道miRNA在肿瘤发生、进展和转移中发挥重要作用。本研究旨在探索DLBCL两种主要亚型中差异表达的miRNA及其靶基因。通过构建调控网络鉴定枢纽miRNA,并利用DLBCL的实验和外周血样本探索差异miRNA和mRNA的功能及机制。利用基因表达综合数据库(GEO)数据集鉴定与两种DLBCL亚型相关的差异表达miRNA和基因。加权基因共表达网络分析表明,一个基因模块与GCB亚型患者的较好预后相关。通过构建调控网络并对临床样本和细胞系进行qPCR验证,miR-129-5p被鉴定为ABC和GCB亚型之间重要的差异miRNA。利用荧光素酶报告基因实验证实了DLBCL中miR-129-5p与AT丰富交互结构域3A(ARID3A)之间的负相关关系。miR-129-5p的过表达和ARID3A的敲低抑制了SU-DHL-2(ABC型)细胞的增殖,并通过Janus激酶(JAK)和信号转导及转录激活因子6(STAT6)信号通路促进其凋亡。此外,miR-129-5p的抑制和ARID3A的过表达促进了DB和SU-DHL-6(GCB型)细胞的增殖并减少其凋亡。在DB和SU-DHL-6中抑制miR-129-5p并过表达ARID3A可通过增加程序性死亡受体配体1(PD-L1)的表达促进免疫逃逸,而PD-L1的表达是由ARID3A转录激活的。总之,我们首次表明mir-129-5P/ARID3A负反馈环通过调节程序性死亡蛋白1(PD-1)/PD-L1来调控DLBCL的进展和免疫逃逸。